Prezzo di chiusura
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
46,73 CNY | -3,63% | -3,41% | -27,53% |
Attività
Numero di dipendenti: 2 042
Vendite per attività
CNY in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Clinical Trial Operation
49,1
%
| 300 | 47,0 % | 354 | 49,1 % | +18,32% |
Clinical Trial Site Management
25,8
%
| 154 | 24,2 % | 186 | 25,8 % | +20,58% |
Data Management and Statistical Analysis
11,0
%
| 73 | 11,4 % | 80 | 11,0 % | +9,87% |
Biological Sample Testing
5,1
%
| 45 | 7,0 % | 36 | 5,1 % | -18,61% |
Clinical Pharmacology
5,0
%
| 32 | 5,0 % | 36 | 5,0 % | +12,39% |
Clinical Trial Consulting
4,0
%
| 34 | 5,4 % | 29 | 4,0 % | -16,12% |
Vendite per regione
CNY in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
China
93,5
%
| 605 | 94,9 % | 674 | 93,5 % | +11,47% |
Overseas
6,5
%
| 32 | 5,1 % | 47 | 6,5 % | +44,57% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Jie Wu
CEO | Chief Executive Officer | 63 | 22/08/08 |
Shu Qi Li
FOU | Founder | 59 | 22/08/08 |
Qian Zhao
DFI | Director of Finance/CFO | 40 | 01/02/14 |
Hong Guan
CHM | Chairman | 47 | 01/04/10 |
Yan Zheng
CTO | Chief Tech/Sci/R&D Officer | 40 | 01/07/09 |
Wei Guo Zhang
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/04/14 |
Wei Wang
BRD | Director/Board Member | 46 | 01/08/08 |
Le Yan Teng
BRD | Director/Board Member | 52 | 01/10/09 |
Gang Chen
PRN | Corporate Officer/Principal | 68 | 01/07/16 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Li Peng Lan
BRD | Director/Board Member | 61 | 31/08/23 |
Le Yan Teng
BRD | Director/Board Member | 52 | 01/10/09 |
Shu Qi Li
FOU | Founder | 59 | 22/08/08 |
Hong Bei Zheng
BRD | Director/Board Member | 58 | 01/01/15 |
Jie Wu
CEO | Chief Executive Officer | 63 | 22/08/08 |
Wei Wang
BRD | Director/Board Member | 46 | 01/08/08 |
Hong Li
BRD | Director/Board Member | 55 | 01/09/15 |
Lu Yang
BRD | Director/Board Member | 42 | 01/09/15 |
Wei Guo Zhang
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/04/14 |
Yan Zheng
CTO | Chief Tech/Sci/R&D Officer | 40 | 01/07/09 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 96 000 000 | 30 192 000 ( 31,45 %) | 0 | 31,45 % |
Coordinate società
R&G PharmaStudies Co., Ltd.
North Tower, Huatong Building 19 Chegongzhuang West Road
100048, Beijing
+
http://www.rg-pharma.comSettore
Vendite per attività
Vendite per regione
Revisioni EPS
Utili annuali - Indice di sorpresa
Variaz. 1 gen. | Capi. | |
---|---|---|
-27,53% | 621 Mln | |
+20,68% | 85,55 Mrd | |
-29,31% | 70,07 Mrd | |
+9,23% | 29,06 Mrd | |
-8,63% | 17,51 Mrd | |
+2,14% | 17,39 Mrd | |
+0,39% | 15,38 Mrd | |
+6,47% | 13,4 Mrd | |
+68,09% | 12,87 Mrd | |
+6,43% | 12,77 Mrd |
- Borsa valori
- Azioni
- Azione 301333
- Società R&G PharmaStudies Co., Ltd.